Identification
- Summary
Cytidine is a drug used to manage neuropsychiatric deficits associated with cerebrovascular diseases in combination with uridine.
- Generic Name
- Cytidine
- DrugBank Accession Number
- DB02097
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Cytidine (DB02097)
- Weight
- Average: 243.2166
Monoisotopic: 243.085520541 - Chemical Formula
- C9H13N3O5
- Synonyms
- 1-beta-D-Ribofuranosylcytosine
- 1β-D-ribofuranosylcytosine
- 4-amino-1-β-D-ribofuranosylpyrimidin-2(1H)-one
- 4-amino-1β-D-ribofuranosyl-2(1H)-pyrimidinone
- Citidina
- Cytidin
- Cytosine riboside
- Zytidin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UUridine-cytidine kinase 2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Pyrimidine nucleosides
- Sub Class
- Not Available
- Direct Parent
- Pyrimidine nucleosides
- Alternative Parents
- Glycosylamines / Pentoses / Pyrimidones / Aminopyrimidines and derivatives / Imidolactams / Hydropyrimidines / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Azacyclic compounds show 6 more
- Substituents
- Alcohol / Amine / Aminopyrimidine / Aromatic heteromonocyclic compound / Azacycle / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine / Imidolactam show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- cytidines (CHEBI:17562) / Ribonucleosides (C00475)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5CSZ8459RP
- CAS number
- 65-46-3
- InChI Key
- UHDGCWIWMRVCDJ-XVFCMESISA-N
- InChI
- InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1
- IUPAC Name
- 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
- SMILES
- NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
References
- Synthesis Reference
Kiyoshi Nakayama, Hiroshi Hagino, "Method for preparing cytidine diphosphate choline." U.S. Patent USRE0288861, issued August 15, 1972.
USRE0288861- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000089
- KEGG Drug
- D07769
- KEGG Compound
- C00475
- PubChem Compound
- 6175
- PubChem Substance
- 46507502
- ChemSpider
- 5940
- ChEBI
- 17562
- ChEMBL
- CHEMBL95606
- ZINC
- ZINC000002583632
- PDBe Ligand
- CTN
- Wikipedia
- Cytidine
- PDB Entries
- 1uej / 2fr6 / 2v34 / 3p0z / 3p10 / 3qhd / 3t80 / 3tka / 3w34 / 3w8r … show 16 more
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous Injection, powder, for solution Intramuscular; Intravenous Solution Oral Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 43.8 mg/mL ALOGPS logP -2.2 ALOGPS logP -2.8 Chemaxon logS -0.74 ALOGPS pKa (Strongest Acidic) 12.55 Chemaxon pKa (Strongest Basic) -2.6 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 128.61 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 54.54 m3·mol-1 Chemaxon Polarizability 22.4 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9623 Blood Brain Barrier + 0.9465 Caco-2 permeable - 0.8887 P-glycoprotein substrate Non-substrate 0.798 P-glycoprotein inhibitor I Non-inhibitor 0.9686 P-glycoprotein inhibitor II Non-inhibitor 0.9532 Renal organic cation transporter Non-inhibitor 0.9519 CYP450 2C9 substrate Non-substrate 0.793 CYP450 2D6 substrate Non-substrate 0.8613 CYP450 3A4 substrate Non-substrate 0.6203 CYP450 1A2 substrate Non-inhibitor 0.9543 CYP450 2C9 inhibitor Non-inhibitor 0.9638 CYP450 2D6 inhibitor Non-inhibitor 0.9497 CYP450 2C19 inhibitor Non-inhibitor 0.9489 CYP450 3A4 inhibitor Non-inhibitor 0.9609 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.981 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.9158 Biodegradation Not ready biodegradable 0.7807 Rat acute toxicity 1.7184 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.983 hERG inhibition (predictor II) Non-inhibitor 0.911
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Uridine kinase activity
- Specific Function
- Phosphorylates uridine and cytidine to uridine monophosphate and cytidine monophosphate. Does not phosphorylate deoxyribonucleosides or purine ribonucleosides. Can use ATP or GTP as a phosphate don...
- Gene Name
- UCK2
- Uniprot ID
- Q9BZX2
- Uniprot Name
- Uridine-cytidine kinase 2
- Molecular Weight
- 29298.92 Da
References
Drug created at June 13, 2005 13:24 / Updated at May 07, 2021 21:06